Related Experiment Videos
Recombinant factor VIIa (Novoseven) as a hemostatic agent
1Novo Nordisk A/S, Research and Development, Maaloev, Denmark.
Seminars in Hematology
|December 6, 2001
Summary
Recombinant activated factor VII (rFVIIa) effectively manages bleeding in hemophilia patients. Dosing strategies vary based on bleed severity, with potential for higher doses needed in specific cases.
Area of Science:
- Hematology
- Pharmacology
Background:
- Recombinant activated factor VII (rFVIIa) is used for bleeding in hemophilia A and B.
- It is effective regardless of inhibitor status.
Purpose of the Study:
- To summarize clinical experience with NovoSeven (rFVIIa) in hemophilia patients.
- To provide dosing recommendations for various bleeding scenarios.
Main Methods:
- Review of clinical experience with over 6,500 patients and 180,000 doses.
- Analysis of dosing regimens for different bleeding severities and surgical interventions.
Main Results:
- Standard dosing: 90-110 microg/kg bolus every 2 hours.
- Mild/moderate bleeds: 2-3 doses for hemostasis.
- Severe bleeds/major surgery: Continuous dosing for 24 hours, then extended intervals.
- In vitro data suggests higher doses may be needed without FVIII, FIX, FXI.
Conclusions:
- rFVIIa is a valuable tool for managing bleeding in hemophilia.
- Dosing should be tailored to clinical situations.
- Further research may be needed for optimal dosing in specific deficiencies.